Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendon Binneman

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Schizophrenia Bulletin|June 15, 2007
Wayne Fenton's impact on industryAlan Breier, Larry Alphs, Brendon Binneman
The American Journal of Psychiatry|April 17, 2008
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depressionBrendon Binneman, Douglas Feltner, Sheela Kolluri, et al.
Innovations in Clinical Neuroscience|May 4, 2018
Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety DisorderSteven D Targum, Christopher Murphy, Jibran Khan, et al.
Journal of Clinical Psychopharmacology|December 12, 2018
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety DisorderArthur Simen, Mark Whitlock, Ruolun Qiu, et al.
Schizophrenia Research|November 5, 2002
Longitudinal study of symptoms and cognitive function in chronic schizophreniaCatherine Hughes, Veena Kumari, William Soni, et al.
Alzheimer'S Research & Therapy|April 7, 2018
A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezilTerence Fullerton, Brendon Binneman, William David, et al.
Journal of the Neurological Sciences|August 15, 2018
Evaluation of the use of the Scale for the Assessment and Rating of Ataxia (SARA) in healthy volunteers and patients with schizophreniaNina Shaafi Kabiri, Sana Syed, Taha Bali, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB studyJaren W Landen, Niels Andreasen, Carol L Cronenberger, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Cerebral metabolic effects of intravenous glycine in healthy human subjectsAlexander Neumeister, Richard Carson, Shannan Henry, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 18, 2013
Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation studyIzuru Miyoshi, Yoko Fujimoto, Masahito Yamada, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Schizophrenia Bulletin|June 15, 2007
Wayne Fenton's impact on industryAlan Breier, Larry Alphs, Brendon Binneman
The American Journal of Psychiatry|April 17, 2008
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depressionBrendon Binneman, Douglas Feltner, Sheela Kolluri, et al.
Innovations in Clinical Neuroscience|May 4, 2018
Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety DisorderSteven D Targum, Christopher Murphy, Jibran Khan, et al.
Journal of Clinical Psychopharmacology|December 12, 2018
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety DisorderArthur Simen, Mark Whitlock, Ruolun Qiu, et al.
Schizophrenia Research|November 5, 2002
Longitudinal study of symptoms and cognitive function in chronic schizophreniaCatherine Hughes, Veena Kumari, William Soni, et al.
Alzheimer'S Research & Therapy|April 7, 2018
A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezilTerence Fullerton, Brendon Binneman, William David, et al.
Journal of the Neurological Sciences|August 15, 2018
Evaluation of the use of the Scale for the Assessment and Rating of Ataxia (SARA) in healthy volunteers and patients with schizophreniaNina Shaafi Kabiri, Sana Syed, Taha Bali, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB studyJaren W Landen, Niels Andreasen, Carol L Cronenberger, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Cerebral metabolic effects of intravenous glycine in healthy human subjectsAlexander Neumeister, Richard Carson, Shannan Henry, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 18, 2013
Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation studyIzuru Miyoshi, Yoko Fujimoto, Masahito Yamada, et al.
Pageof 2